North Chicago-based AbbVie announced late Wednesday that it plans to acquire a California biopharmaceutical company whose signature drug is used to treat blood cancers. The deal is valued at $21 billion, AbbVie said.
Ellen Jean Hirst, Chicago Tribune: Living
Wed, 03/04/2015 - 10:47pm
North Chicago-based AbbVie announced late Wednesday that it plans to acquire a California biopharmaceutical company whose signature drug is used to treat blood cancers. The deal is valued at $21 billion, AbbVie said.